The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.
Early breast cancer
Human Epidermal Growth Factor Receptor 2 (HER2)
Pathological complete response (pCR)
Prognosis
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
10
03
2024
accepted:
10
04
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
aheadofprint
Résumé
Many patients with early breast cancer (eBC) undergoing neoadjuvant chemotherapy do not achieve pathological complete response (pCR), which is a prognostic factor. We examined the role of HER2-low expression in predicting pCR and prognosis in HER2-negative eBC. We evaluated patients with stage I-III HER2-negative BC, treated between 2013 and 2023 at The Royal Marsden NHS Foundation Trust, London. Tumors were classified based on estrogen receptor (ER) status and into HER2-low and HER2-zero subgroups. We analyzed pCR rates, relapse-free survival (RFS) and overall survival (OS). 754 patients were included in the analysis. pCR rate was 8.9% in the ER+ /HER2-low, 16.5% in the ER+ /HER2-zero, 38.9% in the ER- ER-/HER2-low and 35.9% in the ER-/HER2-zero eBC (p < 0.001). Multivariable analysis showed a significantly lower pCR rate in HER2-low compared to HER2-zero BC in the ER+ subgroup. At a median follow-up of 63.8 months (59.9-67.4), we observed longer OS in HER2-low compared to HER2-zero patients in the overall and in the ER+ population. There was no predictive or prognostic impact of HER2-low status in the ER- population. This study supports the interpretation of HER2 status as a possible prognostic and predictive biomarker for HER2-negative eBC, especially among patients with ER+ disease.
Identifiants
pubmed: 38743174
doi: 10.1007/s10549-024-07336-4
pii: 10.1007/s10549-024-07336-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. The Lancet. https://clinicaltrials.gov/study/NCT04622319#study-record-dates
Gentile D et al (2023) Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients. Breast. https://clinicaltrials.gov/study/NCT04622319#study-record-dates
Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, The BS (2018) Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. https://clinicaltrials.gov/study/NCT04622319#study-record-dates
Battisti NML et al (2020) Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. Breast Cancer Res Treat. https://clinicaltrials.gov/study/NCT04622319#study-record-dates
Schmid P et al (2020) Pembrolizumab for early triple-negative breast cancer. New Engl J Med. https://clinicaltrials.gov/study/NCT04622319#study-record-dates
Derouane F et al (2022) Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine. Cancers (Basel) 14(16). https://doi.org/10.3390/cancers14163876 .
Schlam I, Tolaney SM, Tarantino P (2023) How I treat HER2-low advanced breast cancer. Breast 67:116–123. https://doi.org/10.1016/j.breast.2023.01.005
doi: 10.1016/j.breast.2023.01.005
pubmed: 36669993
pmcid: 9982266
Modi S et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20. https://doi.org/10.1056/nejmoa2203690
doi: 10.1056/nejmoa2203690
pubmed: 35665782
pmcid: 10561652
Trastuzumab Deruxtecan (T-DXd) alone or in sequence with THP, Versus Standard Treatment (ddAC-THP), in HER2-positive early breast cancer. https://clinicaltrials.gov/study/NCT05113251
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in high-risk HER2-positive participants with residual invasive breast cancer following neoadjuvant therapy (DESTINY-Breast05). https://clinicaltrials.gov/study/NCT04622319#study-record-dates
Hammond MEH et al (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7)
Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast. J Clin Oncol 31(31):3997–4013. https://doi.org/10.1200/JCO.2013.50.9984
doi: 10.1200/JCO.2013.50.9984
pubmed: 24101045
Schettini F et al (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer 7(1). https://doi.org/10.1038/s41523-020-00208-2
Tarantino P et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38(17):1951–1962. https://doi.org/10.1200/JCO.19.02488
doi: 10.1200/JCO.19.02488
pubmed: 32330069
Von Minckwitz G et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. https://doi.org/10.1200/JCO.2011.38.8595
doi: 10.1200/JCO.2011.38.8595
Dowling RJO et al (2019) Toronto workshop on late recurrence in estrogen receptor-positive breast cancer: Part 1: Late Recurrence: current understanding, clinical considerations. JNCI Cancer Spectr 3(4):1–10. https://doi.org/10.1093/jncics/pkz050
doi: 10.1093/jncics/pkz050
Denkert C et al (2021) Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 22(8):1151–1161. https://doi.org/10.1016/S1470-2045(21)00301-6
doi: 10.1016/S1470-2045(21)00301-6
pubmed: 34252375
Kent Osborne RSC (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233–247. https://doi.org/10.1146/annurev-med-070909-182917.MECHANISMS
doi: 10.1146/annurev-med-070909-182917.MECHANISMS
pubmed: 20887199
Petrelli F et al (2023) Prognostic value of HER2-low status in ER+ early breast cancer: A systematic review and meta-analysis. Anticancer Res 43(10):4303–4313. https://doi.org/10.21873/anticanres.16625
de Nonneville A et al (2022) Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer 176:181–188. https://doi.org/10.1016/j.ejca.2022.09.017
doi: 10.1016/j.ejca.2022.09.017
pubmed: 36257173
Tarantino P et al (2022) Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol 8(8):1177–1183. https://doi.org/10.1001/jamaoncol.2022.2286
doi: 10.1001/jamaoncol.2022.2286
pubmed: 35737367
pmcid: 9227690
Ilie SM et al (2023) Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy. Breast Cancer 0123456789. https://doi.org/10.1007/s12282-023-01490-1
Neoadjuvant pyrotinib versus placebo combined with chemotherapy in HR-positive and HER2-low early breast cancer. https://classic.clinicaltrials.gov/ct2/show/NCT06144944?term=early&cond=HER2+Low+Breast+Carcinoma&draw=2&rank=1. Accessed 28 Jan 2024
Trastuzumab deruxtecan alone or in combination with anastrozole for the treatment of early stage HER2 low, hormone receptor positive breast cancer. https://classic.clinicaltrials.gov/ct2/show/NCT04553770?term=early&cond=HER2+Low+Breast+Carcinoma&draw=2&rank=4. Accessed 28 Jan 2024
Ergun Y, Ucar G, Akagunduz B (2023) Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis. Cancer Treat. Rev. 115:102538. https://doi.org/10.1016/j.ctrv.2023.102538
doi: 10.1016/j.ctrv.2023.102538
pubmed: 36898351
Kang S et al (2022) Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. Eur J Cancer 176:30–40. https://doi.org/10.1016/j.ejca.2022.08.031
doi: 10.1016/j.ejca.2022.08.031
pubmed: 36183652
Fernandez AI et al (2022) Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 8(4):1–4. https://doi.org/10.1001/jamaoncol.2021.7239
doi: 10.1001/jamaoncol.2021.7239
pubmed: 35113160
pmcid: 8814969
Lambein K et al (2013) Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol 140(4):561–566. https://doi.org/10.1309/AJCP4A7KTAYHZSOE
doi: 10.1309/AJCP4A7KTAYHZSOE
pubmed: 24045554
Tarantino P et al (2023) ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 34(8). https://doi.org/10.1016/j.annonc.2023.05.008